

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	GENERA BIOSYSTEMS LIMITED (ASX:GBI)
ABN	69 098 663 837

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Lou Panaccio
Date of last notice	6 June 2014

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Indirect (1) Shares held by Tercus Pty Ltd <Panaccio Super Fund A/C>, an entity in which Lou Panaccio has an interest.
Date of change	14 July 2014
No. of securities held prior to change	Direct 300,000 options exercisable at \$0.50 (50 cents) on or before 28 November 2016 Indirect(1) 734,165 fully paid ordinary shares 2,500,000 options exercisable at \$0.15 (15 cents) on or before 2 December 2017.
Class	Fully Paid Ordinary Shares.
Number acquired	20,216
Number disposed	Nil.

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Deemed issue price of \$6,000
No. of securities held after change	Direct 300,000 options exercisable at \$0.50 (50 cents) on or before 28 November 2016 Indirect(1) 754,381 fully paid ordinary shares 2,500,000 options exercisable at \$0.15 (15 cents) on or before 2 December 2017.
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issued in lieu of June 2014 Directors fees as approved at the Annual General Meeting of Shareholders on 28 November 2013.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	Yes
If so, was prior written clearance provided to allow the trade to proceed during this period?	Yes
If prior written clearance was provided, on what date was this provided?	The Board approved the issue of shares on 14 July 2014 as previously approved by shareholders at the Company's 2013 Annual General Meeting.

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	GENERA BIOSYSTEMS LIMITED (ASX:GBI)
ABN	69 098 663 837

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Karl Poetter
Date of last notice	6 June 2014

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Indirect (1) Mr Karl Frederick Poetter & Dr Sarah May Russell, an entity in which Karl Poetter has an interest in.
Date of change	14 July 2014
No. of securities held prior to change	Direct 1,567,787 fully paid ordinary shares 300,000 options exercisable at \$0.15 (15 cents) on or before 2 December 2017 Indirect (1) 93,900 fully paid ordinary shares.
Class	Fully Paid Ordinary Shares.
Number acquired	25,384
Number disposed	Nil

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Deemed issue price of \$7,534
No. of securities held after change	Direct 1,593,171 fully paid ordinary shares 300,000 options exercisable at \$0.15 (15 cents) on or before 2 December 2017 Indirect (1) 93,900 fully paid ordinary shares.
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issued in lieu of June 2014 Directors fees as approved at the Annual General Meeting of Shareholders on 28 November 2013

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	Yes
If so, was prior written clearance provided to allow the trade to proceed during this period?	Yes
If prior written clearance was provided, on what date was this provided?	The Board approved the issue of shares on 14 July 2014 as previously approved by shareholders at the Company's 2013 Annual General Meeting.

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	GENERA BIOSYSTEMS LIMITED (ASX:GBI)
ABN	69 098 663 837

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Richard Nicholas Hannebery
Date of last notice	6 June 2014

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Indirect (1) Shares held by Robyn Gould (spouse of Richard Hannebery) Indirect (2) Joluk Investments Pty Ltd, an entity in which Richard Hannebery has an interest Indirect (3) EG Capital Pty Limited, an entity in which Richard Hannebery has an interest Indirect (4) Silicia Investments Pty Ltd, an entity in which Richard Hannebery has an interest
Date of change	14 July 2014

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

No. of securities held prior to change	282,580 fully paid ordinary shares. <u>Indirect(1)</u> 2,005,000 fully paid ordinary shares <u>Indirect (2)</u> 230,000 fully paid ordinary shares <u>Indirect (3)</u> 717,110 fully paid ordinary shares. <u>Indirect (4)</u> 2,500,000 options exercisable at \$0.15 (15 cents) on or before 2 December 2017.
Class	Fully Paid ordinary Shares
Number acquired	20,216
Number disposed	Nil
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Deemed issue price of \$6,000
No. of securities held after change	<u>Direct</u> 282,580 fully paid ordinary shares. <u>Indirect(1)</u> 2,005,000 fully paid ordinary shares <u>Indirect (2)</u> 230,000 fully paid ordinary shares <u>Indirect (3)</u> 737,326 fully paid ordinary shares. <u>Indirect (4)</u> 2,500,000 options exercisable at \$0.15 (15 cents) on or before 2 December 2017.
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issued in lieu of June 2014 Directors fees as approved at the Annual General Meeting of Shareholders on 28 November 2013.

+ See chapter 19 for defined terms.

For personal use only

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	Yes
If so, was prior written clearance provided to allow the trade to proceed during this period?	Yes
If prior written clearance was provided, on what date was this provided?	The Board approved the issue of shares on 14 July 2014 as previously approved by shareholders at the Company's 2013 Annual General Meeting.

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	GENERA BIOSYSTEMS LIMITED (ASX:GBI)
ABN	69 098 663 837

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	David Symons
Date of last notice	6 June 2014

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
Date of change	10 & 14 July 2014
No. of securities held prior to change	1,026,645 fully paid ordinary shares. 1,250,000 options exercisable at \$0.15 (15 cents) on or before 2 December 2017. 250,000 options exercisable at \$0.625 (62.5 cents) on or before 10 July 2014
Class	Fully paid ordinary shares Unlisted options
Number acquired	10,108 fully paid ordinary shares
Number disposed	250,000 options exercisable at \$0.625 (62.5 cents) on or before 10 July 2014
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Deemed issue price of \$3,000

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	1,036,753 fully paid ordinary shares. 1,250,000 options exercisable at \$0.15 (15 cents) on or before 2 December 2017.
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issued in lieu of May 2014 Directors fees as approved at the Annual General Meeting of Shareholders on 28 November 2013. The unlisted options noted above, expired unexercised.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	Yes
If so, was prior written clearance provided to allow the trade to proceed during this period?	Yes
If prior written clearance was provided, on what date was this provided?	The Board approved the issue of shares on 14 July 2014 as previously approved by shareholders at the Company's 2013 Annual General Meeting.

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	GENERA BIOSYSTEMS LIMITED (ASX:GBI)
ABN	69 098 663 837

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	James Kalokerinos
Date of last notice	6 June 2014

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Indirect (1) Shares held by Mr James Peter Kalokerinos & Mrs Mary-Anne Elizabeth Kalokerinos <Kalokerinos Superfund>, an entity in which James Kalokerinos has an interest.
Date of change	14 July 2014
No. of securities held prior to change	Indirect(1) 456,029 fully paid ordinary shares 300,000 options exercisable at \$0.50 (50 cents) on or before 28 November 2016 300,000 options exercisable at \$0.15 (15 cents) on or before 2 December 2017.
Class	Fully Paid Ordinary Shares
Number acquired	10,108
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Deemed issue price of \$3,000

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	<u>Indirect(1)</u> 466,137 fully paid ordinary shares 300,000 options exercisable at \$0.50 (50 cents) on or before 28 November 2016 300,000 options exercisable at \$0.15 (15 cents) on or before 2 December 2017.
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issued in lieu of June 2014 Directors fees as approved at the Annual General Meeting of Shareholders on 28 November 2013.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	Yes
If so, was prior written clearance provided to allow the trade to proceed during this period?	Yes
If prior written clearance was provided, on what date was this provided?	The Board approved the issue of shares on 14 July 2014 as previously approved by shareholders at the Company's 2013 Annual General Meeting.

+ See chapter 19 for defined terms.

For personal use only